Tectonic Therapeutic reports ‘positive’ data from Phase 1b trial for TX45
Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...
bovnews8m
Tectonic Therapeutics’ (TECX) Stock Rockets: What’s Behind the Surge?
Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...
BioSpace23h
Lilly Cuts Mid-stage Relaxin Study in Chronic Kidney Disease for ‘Lack of Foreseeable Clinical Benefit’
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
Leerink maintains Tectonic stock Outperform with $69 target
Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF ...
Tectonic Therapeutic stock soars on positive trial data
The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...
Tectonic shares tumble after rival drug trial termination
Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE:LLY) for chronic ...
Seeking Alpha25d
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly ...